Entering text into the input field will update the search result below

Kiniksa Pharmaceuticals GAAP EPS of -$0.18, revenue of $48.3M

May 02, 2023 8:30 AM ETKiniksa Pharmaceuticals, Ltd. (KNSA) StockBy: Urvi Shah, SA News Editor
  • Kiniksa Pharmaceuticals press release (NASDAQ:KNSA): Q1 GAAP EPS of -$0.18.
  • Revenue of $48.3M (+50.0% Y/Y).
  • Net loss for the first quarter of 2023 was $12.3 million, compared to a net loss of $25.2 million for the first quarter of 2022.
  • As of March 31, 2023, Kiniksa had $187.5 million of cash, cash equivalents, and short-term investments and no debt.
  • Financial Guidance
  • Kiniksa now expects ARCALYST net product revenue for the full-year 2023 of between $200 million and $215 million vs $220.75M Consensus
  • Kiniksa now expects that its cash and cash equivalents will fund its current operating plan into at least 2026.

Recommended For You

More Trending News

About KNSA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
KNSA--
Kiniksa Pharmaceuticals, Ltd.